Report initial data from the Phase 1 DAVIO clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- November 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we are looking forward to seeing initial data as early as the second half of this year.”
What we found
Evidence strength A What the grades mean
The company reported positive interim six-month safety and efficacy data from the Phase 1 DAVIO clinical trial in November 2021, which falls within the second half of 2021.
-
A EyePoint Pharmaceuticals, Inc. 10-K filed 2022-03-14
“we reported positive interim six-month safety and efficacy data in November 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 1 DAVIO clinical trial initial data
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you EyePoint Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-EYPT-022604 · Corrections policy